



Alemtuzumab

Revised: November 15, 2023.

CASRN: 216503-57-0

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of alemtuzumab during breastfeeding. Because alemtuzumab is a large protein molecule with a molecular weight of 145,454 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Until more data become available, alemtuzumab should be used with caution or avoided in nursing mothers during treatment for multiple sclerosis, especially while nursing a newborn or preterm infant.[3-7] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[7] The manufacturer recommends that women not breastfeed during treatment and for at least 3 months following the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Multiple Sclerosis) [Glatiramer](#), [Immune Globulin](#), [Interferon Beta](#)

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

References

1. Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. *Reprod Breed* 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003
2. Anderson PO. Monoclonal antibodies during breastfeeding. *Breastfeed Med* 2021;16:591-3. PubMed PMID: 33956488.
3. Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: A systematic review. *Obstet Gynecol* 2014;124:1157-68. PubMed PMID: 25415167.
4. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. *Mult Scler* 2013;19:835-43. PubMed PMID: 23319073.
5. Almas S, Vance J, Baker T, Hale T. Management of multiple sclerosis in the breastfeeding mother. *Mult Scler Int* 2016;2016:6527458. PubMed PMID: 26966579.
6. Iyer P, Dobson R. Multiple sclerosis in pregnancy: A commentary on disease modification and symptomatic drug therapies. *Neurol Ther* 2023;12:1-10.
7. Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. *Lancet Neurol* 2023;22:350-66. PubMed PMID: 36931808.

Substance Identification

Substance Name

Alemtuzumab

CAS Registry Number

216503-57-0

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Antibodies, Monoclonal, Humanized

Immunosuppressive Agents